ARTBIO Implements Voluntary Clinical Hold of ARTISAN Trial for Lead Asset AB001

CAMBRIDGE, Mass., APRIL 7, 2026 - ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), today announced a voluntary hold in enrollment and dosing in its Phase 1 ARTISAN trial for AB001, following the identification of process-related variability.

With the best interest of patients in mind, the company proactively paused all clinical trial operations and notified the FDA about its decision, which the FDA confirmed. ARTBIO is working closely with regulators to address the process-related variability. Early technical results support confidence in a clear and manageable path forward. ARTBIO continues to advance its mission through rigorous, science-driven development.

About ARTBIO

Cancer is relentless. So are we. At ARTBIO, cancer care is redefined by discovering and developing a new class of Alpha Radioligand Therapies (ARTs), powered by unique 212Pb isotope technology and seamless supply. ARTBIO's unique patient-centric framework rests on three pillars: Bringing therapies that matter to patients, scaling a seamless supply and a radiant team to make it all happen. The company is building on a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway's Radium Hospital. For more information, visit www.artbio.com and follow us on LinkedIn.

ARTBIO Media Contact

MDL Strategic Communications
Michael Lauer
michael@mdlcomms.com